Vertex Pharmaceuticals Inc
Company Profile
Business description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Contact
50 Northern Avenue
BostonMA02210
USAT: +1 617 341-6100
E: investorinfo@vrtx.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
6,100
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,939.70 | 378.00 | 5.00% |
| CAC 40 | 6,896.91 | 203.51 | -2.87% |
| DAX 40 | 19,670.88 | 609.38 | -3.00% |
| Dow JONES (US) | 40,608.45 | 62.52 | 0.15% |
| FTSE 100 | 7,705.87 | 204.66 | -2.59% |
| HKSE | 20,264.49 | 136.81 | 0.68% |
| NASDAQ | 17,124.97 | 574.37 | 3.47% |
| Nikkei 225 | 34,269.71 | 2,555.68 | 8.06% |
| NZX 50 Index | 12,232.46 | 425.91 | 3.61% |
| S&P 500 | 5,456.90 | 474.13 | 9.52% |
| S&P/ASX 200 | 7,742.40 | 367.40 | 4.98% |
| SSE Composite Index | 3,186.81 | 0.00 | 0.00% |